PMID- 17765378
OWN - NLM
STAT- MEDLINE
DCOM- 20080502
LR  - 20220318
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 32
IP  - 1
DP  - 2008 Jan 1
TI  - Yi-gan san for the treatment of borderline personality disorder: an open-label 
      study.
PG  - 150-4
AB  - BACKGROUND: Numerous medications have been tested on patients with borderline 
      personality disorder (BPD). Although many of these medications have been 
      demonstrated to be useful, no clear main treatment for BPD has emerged. Despite 
      the efficacy of some of the medicines, acceptability and side effects have proven 
      to be barriers to their use. Recent studies indicate that the traditional Chinese 
      herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful 
      in treating behavioral and psychological symptoms in dementia patients. We aimed 
      at evaluating both efficacy and safety of yi-gan san in patients with 
      well-defined BPD. METHODS: Twenty female outpatients diagnosed with BPD according 
      to DSM-IV criteria and the revised Diagnostic Interview for Borderlines completed 
      a 12-week open-label study with yi-gan san at an average daily dosage of 
      6.4+/-1.9 g (2.5-7.5 g). Psychometric instruments to assess efficacy included the 
      Brief Psychiatric Rating Scale (BPRS), Hamilton Rating Scales for Depression 
      (HAM-D), Global Assessment of Functioning (GAF), Clinical Global Impression Scale 
      (CGI), and Aggression Questionnaire (AQ). RESULTS: Most psychometric scale scores 
      exhibited a highly significant improvement (total BPRS; BPRS somatic concern, 
      anxiety, tension, depressive mood, hostility, suspiciousness, motor retardation, 
      uncooperativeness, and excitement subscale; CGI; GAF; AQ) over time. CONCLUSIONS: 
      In this open-label pilot study, patients treated with YGS showed statistically 
      significant reduction on self-rated and clinician-rated scales. The present 
      findings suggest that yi-gan san might be effective for the treatment of a number 
      of BPD symptoms, including low mood, impulsivity, and aggression.
FAU - Miyaoka, Tsuyshi
AU  - Miyaoka T
AD  - Department of Psychiatry, Shimane University School of Medicine, 89-1 Enyacho, 
      Izumo 693-8501, Japan. miyanyan@med.shimane-u.ac.jp
FAU - Furuya, Motohide
AU  - Furuya M
FAU - Yasuda, Hideaki
AU  - Yasuda H
FAU - Hayashia, Maiko
AU  - Hayashia M
FAU - Inagaki, Takuji
AU  - Inagaki T
FAU - Horiguchi, Jun
AU  - Horiguchi J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20070808
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Yi-Gan San)
SB  - IM
MH  - Adult
MH  - Borderline Personality Disorder/*drug therapy
MH  - Drug Evaluation
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Psychiatric Status Rating Scales
MH  - Psychometrics
EDAT- 2007/09/04 09:00
MHDA- 2008/05/03 09:00
CRDT- 2007/09/04 09:00
PHST- 2007/05/17 00:00 [received]
PHST- 2007/07/31 00:00 [revised]
PHST- 2007/07/31 00:00 [accepted]
PHST- 2007/09/04 09:00 [pubmed]
PHST- 2008/05/03 09:00 [medline]
PHST- 2007/09/04 09:00 [entrez]
AID - S0278-5846(07)00268-0 [pii]
AID - 10.1016/j.pnpbp.2007.07.026 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):150-4. doi: 
      10.1016/j.pnpbp.2007.07.026. Epub 2007 Aug 8.